sulfasalazine

(redirected from Azulfidine en-tabs)
Also found in: Medical.

sul·fa·sal·a·zine

 (sŭl′fə-săl′ə-zēn′)
n.
A sulfa drug, C18H14N4O5S, used to treat ulcerative colitis.

[sulfa(pyridine), one of its constituents + sal(icylic acid) + az(o)- + -ine.]
Translations

sulfasalazine

n sulfasalazina
Mentioned in ?
References in periodicals archive ?
AZULFIDINE EN-tabs is the only formulation of sulfasalazine (pronounced: sul-fa-sal-a-zeen) approved by the FDA for the treatment of both juvenile and adult RA.
The FDA's approval of AZULFIDINE EN-tabs for juvenile rheumatoid arthritis gives clinicians in pediatric rheumatology an important new option to effectively manage this condition," said Arthur Weaver, M.
Azulfidine EN-tabs (sulfasalazine delayed release tablets, USP) enteric-coated tablets are for patients with rheumatoid arthritis who have responded inadequately to nonsteroidal anti-inflammatory drugs.
MGI PHARMA is promoting Azulfidine EN-tabs through its rheumatology-focused sales force.
Blitzer, MGI PHARMA's president and chief executive officer said, "MGI's field sales force is now fully trained for promoting Azulfidine EN-tabs to the rheumatology community and is excited about its growth potential in the United States.
MGI PHARMA will promote Azulfidine EN-tabs through its rheumatology-focused sales force as a product with anti-inflammatory and/or immunomodulatory properties.
Blitzer, MGI PHARMA's president and chief executive officer, stated: "By entering into this co-promotion arrangement for Azulfidine EN-tabs with Pharmacia & Upjohn, we have further strengthened our commercial presence in the rheumatology marketplace.
Food and Drug Administration clearance to market Azulfidine EN-tabs Tablets (sulfasalazine delayed release tablets, USP) for the treatment of rheumatoid arthritis (RA) in patients who have responded inadequately to or are intolerant of analgesics or other non-steroidal anti-inflammatory drugs (NSAIDs).